Biotechnology, electronics and life science company MOBILion Systems, Inc. announced on Wednesday a collaboration with Dr Oliver Schmitz from the University of Duisburg-Essen, a specialist in analytical chemistry for complex sample analysis.
This partnership highlights MOBILion's commitment to advancing multiomics research through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology.
Dr Schmitz will integrate MOBILion's latest low mass system into his work on complex sample analysis, including Chinese herbal medicine and multidimensional chromatography workflows. The system addresses limitations of traditional LC-MS and ion mobility technologies, enabling precise and efficient metabolomics discovery. Cleaner, more focused data is achieved by reducing overlapping signals, simplifying molecular identification and interpretation.
MOBILion continues to expand its SLIM-based product pipeline, supporting breakthroughs in proteomics, lipidomics, glycomics, and metabolomics. This collaboration builds on the company's recent progress in proteomics applications and commercial platform development.
INOVIO's INO-3107 Biologics License Application accepted by US FDA
ABL Bio receives upfront payment and equity investment from Eli Lilly
CARsgen Therapeutics submits two IND applications for CT0596 to Chinese regulator
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents